Ischemic heart disease (post-myocardila infarction angina, angina pectoris)
Conditions
Interventions
atenolol-treated group dose: 50 mg QD maximum dose: 100mg Permission to change the dose according to age or symptoms.
benidipine-treated group dose: 4mg BID Permission to change the dos
Sponsors
Nippon Medical School
Nippon Medical School, Chiba Hokusoh hospital, Musashi Kosugi hospital, Tama Nagayama hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. post-myocardial angina healed myocardial infarction or >1 month after acute myocardial infarction under stable conditions 2. angina pectoris >=1mm ST deviation on chest pain was observed and coronary angiography within 6 months revealed 75%<= stenosis Vasospasm Acetylcholineor ergonobin induced vasospasm, catheter-induced vasospasm, or 1mm<= ST elevation on chest pain
Exclusion criteria
Exclusion criteria: 1) previous history of hypersensitivity or intolerance of atenolol or benidipine 2) cardiogenic shock 3)diabetic ketoacidosis, metabolic acidosis 4)severe or symptomatic bradycardia, atrioventricular block (II, III degree), sinoatrial block, sick sinus syndrome 5)critical arrhythmia 6)right ventricular failure with pulmonary hypertension 7)congestive heart failure 8)hypotension 9)severe peripheral arterial disease (gangrene etc) 10)untreated pheochromocytoma 11)any women who is pregnant or breastfeeding, or expecting to conceive within the projected duration of the study 12)severe hepatic failure (total bilirubin >2.0mg/dL) 13)severe renal failure (serum creatinin >3.0mg/dL) 14)infection, paralytic or obstractive ileus 15)ongoing or planning treatment with anti-cancer drugs 16)other serious illness or significant abnormalities that the investigator judges inappropriate for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cardiovascular evetns including myocardial infarction, angina, silent myocardial ischemia, taget lesion revascularization, cerebral infarction, intracerebral hemorrhage | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. all death 2. hospitalization due to heart failure etc 3. renal failure (hemodialysis) | — |
Countries
Japan
Contacts
Public ContactKyoichi Mizuno
Nippon Medical School Department of Internal Medicine, division of cardiology
Outcome results
None listed